C90.0
Conditions
Interventions
Group 1: Trial subjects: Patients having a multiple myeloma and measurable paraprotein levels before the start of treatment with newly diagnosed multiple myeloma or before adjustment of medication wit
Sponsors
Arbeitsgruppe Prof. Bassermann, Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Start/change of treatment of a patient with newly diagnosed/relapsed Multiple Myeloma with measurable paraprotein; performance status ECOG </= 3; Patients have to be treated routinely in the departement of internal medicine III of the university clinics of the technical university Munich.
Exclusion criteria
Exclusion criteria: non-secretory multiple myeloma; HIV/ active Hep B/C infection; other malignant disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Superiority of the analysis of the CD147 serum levels under treatment as an earlier predictive marker for the prediction of treatment response compared to the standard procedure of analysing changes in paraprotein levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Can the CD147 serum level be used as an prognostic biomarker for the prediction of response (CR, VGPR, PR, ORR, etc.), progression free survival (PFS) and overal survival (OS)? Comparison of the CD147 serum levels of patients having multiple myeloma with healthy persons. Is it possible to define a threshold value for the prediction of a worse prognosis concerning response, progression free survival and overall survival? | — |
Countries
Germany
Contacts
Public ContactPhilipp Blüm
Arbeitsgruppe Prof. Bassermann, Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München
Outcome results
None listed